The DOI matches its Crossref record.
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group
Abstract
4508 Background: Octreotide is currently used for the control of symptoms in patients with gastroenteropancreatic neuroendocrine tumors (NETs). However, the ability of long-acting somatostatin analogues to control the growth of well-differentiated metastatic NETs is a matter of debate. The analysis of the first randomized, double-blind, placebo-controlled, multicenter, phase IIIb study of octreotide LAR in patients with metastatic NETs of the midgut is presented. Methods: Treatment-naïve patients with histologically confirmed locally inoperable or metastasized well-differentiated NETs and a Karnofsky index >60 were randomized to receive either octreotide LAR 30 mg/month (mo) or placebo for 18 mos, or until tumor progression or death. The primary endpoint was median time to tumor progression. Secondary endpoints included objective tumor response rate (WHO criteria), measured every 3 mos, as well as symptom control and overall survival. This was a planned interim analysis using the Lan-DeMets error spending approach. Results: Eighty-five patients (n=43 octreotide LAR; n=42 placebo) have been enrolled to date and data from 67 patients with tumor progressions and 16 deaths (n=7 octreotide LAR; n=9 placebo) are included here. Median time to tumor progression in the octreotide LAR and placebo groups were 14.3 mos and 6 mos, respectively (HR: 0.34; 95% CI: 0.20–0.59; P=0.000072). After 6 mos of treatment, stable disease was seen in 67% and 37.2% of patients treated with octreotide LAR and placebo, respectively. Due to the low number of observed deaths, median survival time could not be estimated. Conclusions: Octreotide LAR significantly lengthens median time to tumor progression compared with placebo in patients with metastatic NETs of the midgut. Patients treated with octreotide LAR had a 66% risk reduction of tumor progression compared with patients receiving placebo. Octreotide LAR demonstrates substantial tumor control and shows a more favorable antiproliferative response than placebo as two-thirds of patients treated with octreotide LAR achieved stable disease at 6 mos. [Table: see text]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Neuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
Metadata
- Authors
- Arnold, R., Müller, H., Schade-Brittinger, C., Rinke, A., Klose, K., Barth, P., Wied, M., Mayer, C., Aminossadati, B., & PROMID Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-20
- Volume
- 27
- Issue
- 15_suppl
- Pages
- 4508-4508
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4253360717
- Cited by
- 192
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. https://app.cochat.ai/papers/10.1200/jco.2009.27.15_suppl.4508
- The paper
- Arnold, R., Müller, H., Schade-Brittinger, C., Rinke, A., Klose, K., Barth, P., Wied, M., Mayer, C., Aminossadati, B., & PROMID Study Group. (2009). Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.27.15_suppl.4508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.